News

Jerusalem, Israel, January 5, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that Amir Elstein has joined the Company's board of directors, effective January 1, 2009.Mr. Elstein has been a member of Teva's senior management since 2005. He most recently held the position of Executive Vice President, Global Pharmaceutical Resources. Prior to joining Teva as an executive officer, Mr. Elstein served on the Company's board of directors from 1995 to 2004. Mr. Elstein has resigned his executive position with the Company in order to rejoin its board of directors. "I wou Read More »

Jerusalem, Israel, January 7, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) will host a live audio webcast at the Goldman Sachs Healthcare CEOs Unscripted Conference in New York. William Marth, President and CEO, Teva North America, will present on Thursday, January 8, 2009. What: Teva Presentation at the Goldman Sachs Healthcare CEOs Unscripted Conference in New YorkWho: William Marth, President and CEO, Teva North AmericaWhen: Thursday, January 8, 2009 at 10:45 a.m. ETWhere: www.tevapharm.com or http://cc.talkpoint.com/GOLD006/010709a_mg/?entity=tevausaHow: Live over the Internet Read More »

Jerusalem, Israel, January 8, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) will host a live audio webcast at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Eyal Desheh, Chief Financial Officer and William Marth, President and CEO, Teva North America, will present on Monday, January 12, 2009. What: Teva Presentation at the J.P. Morgan Annual Healthcare Conference in San Francisco, CA.Who: Eyal Desheh, Chief Financial OfficerWilliam Marth, President and CEO, Teva North America When: Monday, January 12, 2009 11 a.m. PTWhere: www.tevapharm.com orhttp://metamee Read More »

Jerusalem, Israel, and Basel, Switzerland, January 20, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Lonza Group Ltd. (SIX: LONN) today announced their agreement to establish a joint venture to develop, manufacture and market a portfolio of biosimilars. Through this joint venture, Lonza and Teva bring together highly complementary capabilities that will significantly advance the partners' efforts to secure a leading position in the emerging biosimilars market.Teva and Lonza will cooperate to develop, manufacture and market a number of affordable, efficacious and safe generic eq Read More »

Jerusalem, Israel, January 27, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its fourth quarter and full year 2008 financial results on Tuesday, February 17, 2009. Teva will host a conference call and live webcast on the same day, at 8:30 a.m. ET to discuss its forth quarter and full year 2008 results and overall business environment. A Question & Answer session will follow this discussion. The earnings release will be available on Teva's web site at www.tevapharm.com prior to the call.Investors and other interested parties may access a live Read More »

Jerusalem, Israel, January 30, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Janssen's antipsychotic agent Risperdal® (Risperidone) Oral Solution, 1 mg/mL. Shipment of this product has commenced. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity. The brand product had annual sales of approximately $78 Read More »

Updated label offers early treatment with COPAXONE®Jerusalem, Israel, February 4, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved an expanded label for COPAXONE® (glatiramer acetate injection) to include the treatment of patients with clinical isolated syndrome (CIS) suggestive of multiple sclerosis (MS). This approval includes 24 EU member countries that take part in the MHRA "mutual recognition procedure". A similar application for the expanded COPAXONE® label is currently und Read More »

Jerusalem, Israel, February 11, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of GlaxoSmithKline's Imitrex® Tablets, 25 mg, 50 mg and 100 mg for treatment of acute migraine attacks. Shipment of this product has commenced.As one of the first companies to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.Annual sales of this prod Read More »

Jerusalem, Israel and Lund, Sweden, February 12, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS), has received a Fast Track designation from the U.S. Food and Drug Administration (FDA). Teva completed enrollment for the first of its two Phase III clinical trials for laquinimod (ALLEGRO) in November 2008 and is currently enrolling RRMS patients globally for the second Phase III study (BRAVO).Drugs designated for Fast Track ar Read More »

--2008 Sales Total $11.1 Billion and Non-GAAP EPS of $2.86----Fourth Quarter Sales Total $2.8 Billion and Non-GAAP EPS of $0.76 ----Annual Cash Flow from Operations of $3.2 Billion-- --Quarterly Cash Flow from Operations of $969 Million----Quarterly Dividend Increased by 33% to NIS 0.60 per Share-- Financial Tables Jerusalem, Israel, February 17, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today reported results for the quarter and full year ended December 31, 2008.Full Year and Fourth Quarter Highlights: *Record annual and quarterly net sales of $11.1 billion and $2.8 Read More »